Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Real-world HF Management in the Philippines: HF ER Study
Author(s): Eugenio B Reyes , Julian Alexander A Huibonhoa , Rogelio V Tangco , et al Added: 12 months ago

Heart Failure
ESC HF 25: The VELOCITY Study
Author(s): Stephen J Greene Added: 11 months ago
ESC HF 25 - VELOCITY shows bypassing an initiation dose of 2.5mg, and and beginning with 5mg vericiguat safe and tolerable in 9/10 patients with heart failure with ejection fraction <45%.Prof Stephen Greene (Duke Clinical Research Institute, US) discusses the findings from VELOCITY (NCT06195930; Bayer), a phase 2b open-label clinical study evaluating the tolerability and safety of an… View more

Heart Failure
Decoding the Future of HF — Key Takeaways from 2024
Author(s): Muthiah Vaduganathan , Orly Vardeny , Added: 1 year ago
Recorded at American Heart Association 2024 in Chicago, Dr Muthiah Vaduganathan (Brigham and Women’s Hospital and Harvard Medical School, Boston, US), Dr Orly Vardeny (University of Minnesota Medical School, Minneapolis, US) and Prof Pardeep Jhund (University of Glasgow, Glasgow, UK) explore cardiometabolic disease in heart failure with mid-range or preserved ejection fraction (HFmrEF and HFpEF)… View more

Heart Failure
AHA 25: The FOOD-HF Trial
Author(s): Ambarish Pandey Added: 5 months ago
AHA Scientific Sessions 2025 – Dr Ambarish Pandey (University of Texas Southwestern Medical Center, US) presents findings from a randomized clinical trial comparing medically tailored meals versus produce supplements on heart failure readmissions and emergency department visits.The study was conducted across two centers in Dallas, Texas. Patients were randomized within two weeks following heart… View more

Prevention & Chronic Conditions

Heart Failure
AHA 25: The POLY-HF Trial
Author(s): Ambarish Pandey Added: 5 months ago
AHA Scientific Sessions 2025 – Dr Ambarish Pandey (University of Texas Southwestern Medical Center, US) presents results from the POLY-HF trial (NCT04633005), evaluating a polypill strategy combining multiple evidence-based medications for heart failure with reduced ejection fraction.This single-center randomized trial enrolled 212 patients with HFrEF (ejection fraction ≤40%) who were not… View more

Heart Failure
HFA 24: The RELIEVE-HF Trial
Author(s): Stefan Anker Added: 1 year ago
HFA 24 - Prof Stefan Anker (Charité Campus Virchow-Klinikum, Berlin, DE) joins us in this succinct interview to outline the findings of the RELIEVE-HF trial (NCT03499236).RELIEVE-HF was designed to evaluate the safety and effectiveness of the V-Wave inter-atrial shunt system to reduce lung congestion in patients with advanced heart failure. 605 participants with New York Heart Association (NYHA)… View more

Heart Failure
SGLT2 Inhibitors in Acute Heart Failure
Author(s): Hugo Prado-Prado , Sergio Raposeiras-Roubín Added: 1 month ago

Heart Failure
Intravenous Ferric Carboxymaltose in FAIR-HF2 Trial Shows No Significant Reduction in Heart Failure Events but Improves Quality of Life
Added: 11 months ago Source:  Radcliffe Cardiology
AUTHOR: Sean DelaneyIn the landmark FAIR-HF2 randomized clinical trial (NCT03036462)1, intravenous (IV) ferric carboxymaltose did not significantly reduce heart failure (HF) hospitalizations or cardiovascular deaths in patients with heart failure and iron deficiency, despite improving patient-reported quality of life outcomes. Results were presented at ACC.252 and concurrently published in JAMA3… View more

Heart Failure
DIGIT-HF: Digitoxin Reduces Primary Outcome in Symptomatic Heart Failure with Reduced Ejection Fraction
Added: 7 months ago Source:  Radcliffe Cardiology
AUTHOR: Yazmin SadikNew findings from the DIGIT-HF trial indicate that adding low-dose digitoxin to guideline-directed medical therapy (GDMT) can reduce the risk of hospitalisation and all-cause mortality in patients with symptomatic heart failure with reduced ejection fraction (HFrEF).¹The results were presented at the European Society of Cardiology (ESC) Congress 2025 and simultaneously… View more

Imaging & Diagnostics

Guidelines & Statements
IMPLEMENT-HF Initiative Raises Quadruple Therapy Use from 4.7% to 44.6% in Heart Failure Care
Added: 11 months ago Source:  Radcliffe Cardiology
AUTHOR: Sean DelaneyA significant improvement in the use of guideline-directed quadruple medical therapy (QMT) for heart failure with reduced ejection fraction (HFrEF) has been achieved through the IMPLEMENT-HF initiative, according to results published in Circulation: Heart Failure1. Over two years, participating hospitals increased the rate of defect-free QMT at discharge dramatically—from just… View more

Heart Failure